Vivek Ramaswamy’s Dermavant team looks to take on Amgen’s $13.4B psoriasis contender Otezla with a promising PhIII readout for a topical rival

John Carroll

Editor & Founder

At first glance, you might not be too impressed with the data from Dermavant’s Phase IIIs for their psoriasis contender tapinarof. The results pale in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Vivek Ramaswamy’s Dermavant team looks to take on Amgen’s $13.4B psoriasis contender Otezla with a promising PhIII readout for a topical rival

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Vivek Ra­maswamy’s Der­ma­vant team looks to take on Am­gen’s $13.4B pso­ri­a­sis con­tender Ote­zla with a promis­ing PhI­II read­out for a top­i­cal ri­val

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Vivek Ramaswamy’s Dermavant team looks to take on Amgen’s $13.4B psoriasis contender Otezla with a promising PhIII readout for a topical rival